KR20090108208A - Compositions for Preventing or Treating Immune Diseases - Google Patents
Compositions for Preventing or Treating Immune Diseases Download PDFInfo
- Publication number
- KR20090108208A KR20090108208A KR1020080033507A KR20080033507A KR20090108208A KR 20090108208 A KR20090108208 A KR 20090108208A KR 1020080033507 A KR1020080033507 A KR 1020080033507A KR 20080033507 A KR20080033507 A KR 20080033507A KR 20090108208 A KR20090108208 A KR 20090108208A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- present
- cells
- dexamethasone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 168
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 93
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 51
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 45
- 229940069521 aloe extract Drugs 0.000 claims abstract description 44
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 68
- 241000894006 Bacteria Species 0.000 claims description 37
- 239000004480 active ingredient Substances 0.000 claims description 35
- 239000004310 lactic acid Substances 0.000 claims description 34
- 235000014655 lactic acid Nutrition 0.000 claims description 34
- 230000036737 immune function Effects 0.000 claims description 29
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 241000186660 Lactobacillus Species 0.000 abstract description 8
- 229940039696 lactobacillus Drugs 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 description 62
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 62
- 230000000694 effects Effects 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 43
- 230000035882 stress Effects 0.000 description 29
- 210000000952 spleen Anatomy 0.000 description 27
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- 239000013642 negative control Substances 0.000 description 24
- 230000028327 secretion Effects 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 20
- 210000001541 thymus gland Anatomy 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 210000004988 splenocyte Anatomy 0.000 description 17
- 240000004371 Panax ginseng Species 0.000 description 16
- 235000008434 ginseng Nutrition 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 230000010261 cell growth Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 230000002992 thymic effect Effects 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002438 stress hormone Substances 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000168720 Panax japonicus Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010032795 CD8 receptor Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000037326 chronic stress Effects 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000218646 Cedrus deodara Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241001527087 Panax vietnamensis Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000009581 alprogen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000008572 bu-zhong-yi-qi-tang Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 및 유산균으로 구성된 군으로부터 선택되는 최소 3종의 성분을 유효성분으로 포함하는 스트레스로부터 야기되는 면역기능 저하를 개선시키는 면역질환 예방 또는 치료용 조성물에 관한 것이다.The present invention is directed to a composition for preventing or treating immune diseases that improves immune function deterioration caused by stress including at least three components selected from the group consisting of red ginseng extract, shiitake mushroom mycelium extract, aloe extract and lactic acid bacteria as an active ingredient. It is about.
일시적으로 받는 스트레스는 외부 감염에 대항하는 면역 시스템의 기능을 강화시켜주지만, 만성적 스트레스는 오히려 면역 기능을 떨어뜨린다. 즉 일시적 스트레스는 면역 기능을 강화시키지만 만성적 스트레스는 인체의 면역 기능을 저하되는 방향으로 신체에 변화를 일으킨다.Temporary stress strengthens the immune system's ability to fight external infections, while chronic stress reduces its immune function. In other words, temporary stress enhances immune function, but chronic stress causes changes in the body in a way that lowers the body's immune function.
사람이 스트레스를 받게 되면 신체로부터 “아드레날린” 및 “코티솔”이라는 스트레스 호르몬이 방출되는데, 이러한 호르몬들은 스트레스를 받는 짧은 기간 동안에 신체에 존재하면서 인체의 면역 시스템이 외부 감염에 대하여 신속하고 효과적으로 대응할 수 있도록 해준다. 그러나 스트레스 호르몬이 신체에 오랫동안 존재하게 되면 상황은 매우 달라진다.When a person is under stress, the body releases stress hormones, "adrenaline" and "cortisol," which are present in the body during the short period of stress, allowing the body's immune system to respond quickly and effectively to external infections. Do it. However, if stress hormones are present in the body for a long time, the situation is very different.
즉 인체의 면역 세포는 외부로부터 침투하는 바이러스 또는 박테리아가 있을 때만 방어 시스템이 가동된다. 또한 평소 신체 내부에는 다량의 면역 세포를 간직할 수 있는 장소가 없기 때문에, 오로지 면역 시스템이 외부 칩임에 자극을 받았을 때만 면역 세포가 일시적으로 증식하게 된다. 스트레스가 오래 지속 되는 사람의 경우, 면역 시스템이 외부의 자극을 받더라도 면역 세포가 증식되지 않기 때문에 신체 방어 능력이 저하된다(Suzanne C et al., Psychological Stress and the Human Immune System: “A Meta-Analytic Study of 30 Years of Inquiry”, Psychological Bulletin, 130(4):601-630(2004)). In other words, the body's immune cells operate only when there is a virus or bacteria penetrating from the outside. In addition, since there is no place inside the body to hold a large amount of immune cells, immune cells temporarily proliferate only when the immune system is stimulated to be an external chip. In people with long-lasting stress, their body's defenses are reduced because immune cells do not proliferate even when the immune system is externally stimulated (Suzanne C et al., Psychological Stress and the Human Immune System: “A Meta-Analytic Study of 30 Years of Inquiry ”, Psychological Bulletin , 130 (4): 601-630 (2004)).
스트레스가 증가하면 혈중 글루코코티코이드(Glucocorticoid) 호르몬의 농도가 증가한다. 즉, 스트레스 증가는 체내 글루코티코이드 호르몬의 증가를 유발시켜 각종 질병 발생 확률을 증가시킨다.As stress increases, the concentration of glucocorticoid hormones in the blood increases. In other words, increased stress causes an increase in glucocorticoid hormones in the body, thereby increasing the probability of developing various diseases.
본 발명에서는 홍삼(Panax ginseng C.A. Meyer) 및 천연 생약재의 글루코코티코이드 호르몬의 일종인 덱사메타손(dexamethasone)의 투여로 유발되는 신체 각 면역기관과 면역세포의 기능의 회복 정도를 평가하여 저하된 면역기능을 강화하는 효과가 있는 시료를 선별하여 면역기능을 강화시키는 조성물을 개발하였다.In the present invention, red ginseng ( Panax ginseng CA Meyer) and dexamethasone, a type of glucocorticoid hormone of natural herbal medicines, to evaluate the recovery of function of each immune system and immune cells in the body To develop a composition that enhances immune function.
본 명세서 전체에 걸쳐 다수의 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Throughout this specification many patent documents are referenced and their citations are indicated. The disclosures of the cited patent documents are incorporated by reference herein in their entirety, and the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly described.
본 발명자들은 스트레스로부터 야기된 면역기능 저하로 발생하는 세균성 감염질환 및 바이러스 질환과 같은 면역질환을 예방 또는 치료할 수 있는 물질을 개발하고자 노력하였다. 그 결과, 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 혼합하여 제조한 조성물을 투여하면, 스트레스 호르몬의 일종인 덱사메타손 투여로 유발된 신체 각 면역기관 및 면역세포의 기능이 회복에 우수한 상승적(synergic) 효과를 가짐을 확인함으로써, 본 발명을 완성하게 되었다. The present inventors have sought to develop a material capable of preventing or treating immune diseases such as bacterial infectious diseases and viral diseases resulting from a decrease in immune function caused by stress. As a result, administration of a composition prepared by mixing red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria, the function of each immune organ and immune cells induced by the administration of dexamethasone, a type of stress hormone, was excellent in recovery ( By confirming that it has a synergic effect, the present invention was completed.
따라서, 본 발명의 목적은 스트레스로부터 야기되는 면역기능 저하를 개선시키는 면역질환 예방 또는 치료용 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a composition for preventing or treating immune diseases that improves immune function degradation caused by stress.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become apparent from the following detailed description, claims and drawings.
본 발명의 양태에 따르면, 본 발명은 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 및 유산균으로 구성된 군으로부터 선택되는 최소 3종의 성분을 유효성분으로 포함하는 스트레스로부터 야기되는 면역기능 저하를 개선시키는 면역질환 예방 또는 치료용 조성물을 제공한다.According to an aspect of the present invention, the present invention provides an immune system for improving immune function deterioration caused by stress including at least three components selected from the group consisting of red ginseng extract, shiitake mushroom mycelium extract, aloe extract and lactic acid bacteria as an active ingredient. Provided is a composition for preventing or treating a disease.
본 발명자들은 스트레스로부터 야기된 면역기능 저하로 발생하는 세균성 감염질환 및 바이러스 질환과 같은 면역질환을 예방 또는 치료할 수 있는 물질을 개발하고자 노력하였다. 그 결과, 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 혼합하여 제조한 조성물을 투여하면, 스트레스 호르몬의 일종인 덱사메타손 투여로 유발된 신체 각 면역기관 및 면역세포의 기능이 회복에 우수한 상승적(synergic) 효과를 가짐을 확인하였다.The present inventors have sought to develop a material capable of preventing or treating immune diseases such as bacterial infectious diseases and viral diseases resulting from a decrease in immune function caused by stress. As a result, administration of a composition prepared by mixing red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria, the function of each immune organ and immune cells induced by the administration of dexamethasone, a type of stress hormone, was excellent in recovery ( synergic) effect.
본 명세서에서 용어 “홍삼(Panax ginseng C.A. Meyer)”은 증기 또는 태양-건조, 바람직하게는 증기를 통하여 인삼을 가열하여 제조된 것을 의미한다. 기재의 편의상, 본 발명은 인삼 또는 홍삼에 적용되는 것으로 기재되어 있다.As used herein, the term “red ginseng ( Panax ginseng CA Meyer) ”means prepared by heating ginseng through steam or sun-drying, preferably steam. For convenience of description, the present invention is described as being applied to ginseng or red ginseng.
홍삼(Panax ginseng C.A. Meyer)은 외적 유해인자에 대한 비특이적인 생체 저항력을 증진시켜 주며 물리적, 화학적 또는 생물학적인 외적 변화에 대해 생체를 정상화시켜 주는 “범적응적 활성(adaptogen)”으로 작용하여 면역기능을 조절해 주는 기능이 있으며, 한편, 홍삼의 주요 효능 성분인 사포닌성분은 면역인자 사멸을 억제시키는 효능이 있다(Choi DH et al., Inhibitory effects of ginseng saponin fractions on dexamethasone-induced thymus apoptosis. Korean J. Ginseng Sci. 21(3): 160-168(1997)).Red Ginseng ( Panax ginseng CA Meyer) enhances nonspecific bio-resistance against external harmful factors and regulates immune function by acting as “adaptogens” that normalize the living body against physical, chemical or biological external changes. On the other hand, saponin, the main potent ingredient of red ginseng, has the effect of suppressing immune factor death (Choi DH et al., Inhibitory effects of ginseng saponin fractions on dexamethasone-induced thymus apoptosis.Korean J. Ginseng Sci 21 (3): 160-168 (1997).
본 명세서에서 용어 “인삼”은 고려삼(Panax ginseng), 회기삼(P. quiquefolius), 전칠삼(P. notoginseng), 죽절삼(P. japonicus), 삼엽삼(P. trifolium), 히말라야삼(P. pseudoginseng), 베트남삼(P. vietnamensis) 및 미국삼 (Panax quinquefolium)을 포함하나, 이에 한정되지 않는다. 바람직하게는, 본 발명에서 이용되는 인삼은 고려삼(Panax ginseng)이다.As used herein, the term “ginseng” refers to Korean ginseng ( Panax ginseng), three sessions (P. quiquefolius), jeonchilsam (P. notoginseng), jukjeol three (P. japonicus), three yeopsam (P. trifolium), Himalayan cedar (P. pseudoginseng), Vietnam, three (P. vietnamensis) and American hemp ( Panax quinquefolium ), but is not limited thereto. Preferably, the ginseng used in the present invention is Korean ginseng ( Panax ginseng ).
본 발명에서 유효성분으로 이용되는 “표고버섯균사체 추출물”은 전통적으로 면역증진에 도움이 되는 것으로 알려진 성분을 많이 함유하고 있는 천연소재이며, 표고버섯 등의 버섯류들은 전통적으로 면역기능 증진에 도움을 주는 약용 및 식품 소재로 사용되어 왔다.Shiitake mushroom mycelium extract used as an active ingredient in the present invention is a natural material containing a lot of ingredients traditionally known to help boost the immune system, mushrooms such as shiitake mushrooms traditionally help to improve immune function It has been used in medicinal and food materials.
본 발명에서 유효성분으로 이용되는 “알로에 추출물”은 전통적으로 인체의 면역기능을 회복하거나 유지하는 효능을 갖고 있으며, 알로에에 함유되어 있는 알프로젠이라는 성분은 알러지 반응을 효과적으로 억제하는 것으로 알려져 있다."Aloe extract" used as an active ingredient in the present invention traditionally has the effect of restoring or maintaining the immune function of the human body, and an ingredient called alprogen contained in aloe is known to effectively suppress allergic reactions.
본 명세서에서 용어“유산균 또는 프로바이오틱스(Probiotics)”는 하버나(Havenar & Vel 1991)등의 정의처럼 일반적으로 “사람이나 동물에게 건조세포나 발효산물의 형태로 투여하여 숙주의 장내 균총을 개선하여 좋은 영향을 주는, 단일 혹은 복합 형태의 생균제”를 의미한다. 상기 유선균은 처음 파스퇴르(1857)가 처음 발견하였으며, 감염이나 종양에 대한 비특이적 방어체계를 강화, 항원에 특이적인 면역반응계에서 보조효과 또는 내분비형 IgA의 합성 촉진작용을 하여 면역기능을 증진하는 효과가 있다.As used herein, the term “lactic acid bacteria or probiotics” is defined as Haberna & Vel 1991 and is generally used to improve the intestinal flora of a host by administering to humans or animals in the form of dry cells or fermented products. Affecting probiotics in single or multiple forms ”. The first bacterium was first discovered by Pasteur (1857), and strengthened the nonspecific defense against infection or tumor, and has an effect of promoting immune function by adjuvant or synthesizing endocrine-type IgA in the antigen-specific immune response system. have.
본 발명의 유효성분으로 이용되는 홍삼 추출물, 표고버섯균사체 추출물 또는 알로에 추출물은 당업계에 공지된 통상적인 추출 과정에서 의해 얻을 수 있는 추출물을 포함한다. 예를 들어, (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코 올 (메탄올, 에탄올, 프로판올, 부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 부틸아세테이트 또는 (h) 1,3-부틸렌글리콜을 추출용매로 하여 얻은 추출물이 본 발명의 유효성분에 포함된다. 바람직하게는, 본 발명의 추출물은 물, 에탄올 또는 에탄올과 물의 혼합용매를 추출용매로 하여 얻은 것이며, 가장 바람직하게는 물을 추출용매로 하여 얻은 것이다.Red ginseng extract, shiitake mycelium extract or aloe extract used as an active ingredient of the present invention includes extracts obtained by conventional extraction procedures known in the art. For example, (a) water, (b) anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol with water, (d) An extract obtained by using acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate or (h) 1,3-butylene glycol as an extraction solvent is included in the active ingredient of the present invention. Preferably, the extract of the present invention is obtained by using water, ethanol or a mixed solvent of ethanol and water as the extraction solvent, and most preferably obtained by using water as the extraction solvent.
한편, 본 발명의 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 본 발명의 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다. 또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 추출물에 포함되는 것이다.On the other hand, it will be apparent to those skilled in the art that the extract of the present invention can be obtained in addition to the above-described extraction solvent, as well as the extract of the present invention exhibiting substantially the same effects using other extraction solvents. In addition, the extract of the present invention includes not only the extract by the above-described extraction solvent, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The fraction is also included in the extract of the present invention.
본 발명의 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.Extracts of the present invention may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
한편, 본 발명에서 이용되는 인삼 또는 홍삼 추출물은 인삼 또는 홍삼 추출물을 장내 세균 또는 유산균을 이용하여 발효한 발효 홍삼액도 포함한다.On the other hand, ginseng or red ginseng extract used in the present invention also includes fermented red ginseng liquid fermented ginseng or red ginseng extract using intestinal bacteria or lactic acid bacteria.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 표고버섯균사체 추출물, 알로에 추출물 및 유산균이다.According to a preferred embodiment of the present invention, the composition of the present invention is shiitake mushroom mycelium extract, aloe extract and lactic acid bacteria.
본 발명의 다른 바람직한 구현예에 따르면, 본 발명의 조성물은 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 및 유산균이다.According to another preferred embodiment of the present invention, the composition of the present invention is red ginseng extract, shiitake mushroom mycelium extract, aloe extract and lactic acid bacteria.
본 발명의 또 다른 바람직한 구현예에 따르면, 본 발명의 조성물에 이용되는 유효성분은 조성물 전체 중량에 대하여 0.1-40%를 포함한다. 보다 바람직하게는 10-30%, 가장 바람직하게는 15-25%이다. 유효성분의 중량이 0.1 중량% 미만일 때는 그 효과가 나타나기 어렵고, 40 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 매우 미약하고, 제형상의 안정성이 확보되지 않는 문제점이 있다.According to another preferred embodiment of the present invention, the active ingredient used in the composition of the present invention comprises 0.1-40% based on the total weight of the composition. More preferably 10-30%, and most preferably 15-25%. When the weight of the active ingredient is less than 0.1% by weight, the effect is less likely to appear, when it exceeds 40% by weight, the increase in effect due to the increase of the content is very weak, there is a problem that the stability in the formulation is not secured.
본 발명의 다른 바람직한 구현예에 따르면, 본 발명의 조성물에 이용되는 유효성분은 유효성분 전체 중량에 대하여 표고버섯균사체 추출물 20-50 중량%, 알로에 추출물 25-40 중량% 및 유산균 25-40 중량%를 포함하고, 보다 바람직하게는 30-40 중량%, 알로에 추출물 30-35 중량% 및 유산균 30-35 중량%, 가장 바람직하게는 중량비 1:1:1로 포함되는 것이다.According to another preferred embodiment of the present invention, the active ingredient used in the composition of the present invention is 20-50% by weight shiitake mycelium extract, 25-40% by weight aloe extract and 25-40% by weight lactic acid bacteria relative to the total weight of the active ingredient It includes, more preferably 30-40% by weight, 30-35% by weight of aloe extract and 30-35% by weight of lactic acid bacteria, and most preferably by weight ratio of 1: 1: 1.
본 발명의 또 다른 바람직한 구현예에 따르면, 본 발명의 조성물에 이용되는 유효성분은 유효성분 전체 중량에 대하여 홍삼 추출물 10-40 중량%, 표고버섯균사체 추출물 20-30 중량%, 알로에 추출물 20-30 중량% 및 유산균 20-30 중량%를 포함하고, 보다 바람직하게는 홍삼 추출물 20-30 중량%, 표고버섯균사체 추출물 23-27 중량%, 알로에 추출물 24-27 중량% 및 유산균 23-26 중량%, 가장 바람직하게는 홍삼 추출물 25 중량%, 표고버섯균사체 추출물 25 중량%, 알로에 추출물 25 중량% 및 유산균 25 중량%이다.According to another preferred embodiment of the present invention, the active ingredient used in the composition of the present invention is 10-40% by weight red ginseng extract, 20-30% by weight shiitake mycelium extract, aloe extract 20-30 based on the total weight of the active ingredient Wt% and lactic acid bacteria 20-30% by weight, more preferably 20-30% by weight of red ginseng extract, 23-27% by weight of shiitake mycelium extract, 24-27% by weight of aloe extract and 23-26% by weight of lactic acid bacteria, Most preferably, 25% by weight of red ginseng extract, 25% by weight of shiitake mycelium extract, 25% by weight of aloe extract and 25% by weight of lactic acid bacteria.
본 명세서에서 용어 “면역질환”은 스트레스로부터 야기되는 면역기능 저하로 발생하는 다양한 질환, 질병 또는 이상 상태를 의미한다. 예를 들어, 류마티스 관절염, 타입 I 당뇨병, 다발성 경화증 및 전신성 홍반 루푸스와 같은 자가면역질환, 천식, 엔세필리티스(encephilitis), 염증성 장염, 만성 폐쇄성 폐질환, 알러지, 폐혈병성 쇼크증, 폐섬유증, 미분화 척추관절증, 미분화 관절병증, 관절염, 염증성 골용해, 및 만성 바이러스 또는 박테리아 감염에 의한 만성 염증과 같은 염증성 질환, 각종 암, 및 감기와 같은 바이러스 질환를 포함하나, 이에 한정되는 것은 아니다.As used herein, the term “immune disease” refers to various diseases, disorders or abnormal conditions resulting from reduced immune function resulting from stress. For example, autoimmune diseases such as rheumatoid arthritis, type I diabetes, multiple sclerosis and systemic lupus erythematosus, asthma, encephilitis, inflammatory enteritis, chronic obstructive pulmonary disease, allergies, pulmonary pulmonary shock, pulmonary fibrosis , Inflammatory diseases such as undifferentiated spondyloarthropathy, undifferentiated arthrosis, arthritis, inflammatory osteolysis, and chronic inflammation caused by chronic viral or bacterial infections, various cancers, and viral diseases such as colds.
본 발명의 다른 바람직한 구현예에 따르면, 본 발명의 조성물이 적용되는 면역질환은 스트레스로부터 야기되는 면역기능저하로 발생하는 암 또는 감기이다.According to another preferred embodiment of the present invention, the immune disease to which the composition of the present invention is applied is a cancer or a cold resulting from a decrease in immune function resulting from stress.
본 발명의 가장 큰 특징은, 본 발명의 유효성분은, 스트레스로부터 유발되어 감소된 비장 및 흉선(면역기관)세포의 수, T세포와 B세포(면역세포), IL-2와 IFN-γ(사이토카인), 및 면역글로불린 M, G1, G2a, G2b 및 G3을 유의적으로 증가시켜 면역기능을 증진시키는 효과가 높다. 하여 스트레스로 인한 면역저하로 야기된 질환, 특히 암 및 감기의 예방 및 개선 효과가 있으며, 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균을 각각 복용하였을 때 보다, 본 발명의 복합 유효성분을 포함하는 조성물을 복용하였을 때 상승적 효과를 가지며, 이러한 면역기능증진 효과는 종래 기능성 식품 조성물에서는 달성할 수 없었던 것이다.The main feature of the present invention, the active ingredient of the present invention, the number of spleen and thymus (immune organ) cells induced by stress, reduced T cells and B cells (immune cells), IL-2 and IFN-γ ( Cytokines), and immunoglobulin M, G1, G2a, G2b and G3 significantly increases the effect of enhancing immune function. It is effective in preventing and improving diseases caused by immunosuppression due to stress, especially cancer and cold, and when the red ginseng extract, shiitake mycelium extract, aloe extract or lactic acid bacteria are respectively taken, the complex active ingredient of the present invention is included. When taking a composition to have a synergistic effect, such an immune function is to be achieved in the conventional functional food composition.
상술한 바와 같이, 본 발명의 조성물은 스트레스로 인한 면역기능 저하를 개선하는 효과를 가지고 있어 스트레스로 고통을 받아 면역기능이 저하된 남녀노소 누구에게나 건강유지 및 증진에 기여할 수 있다.As described above, the composition of the present invention has an effect of improving the immune function lowering due to stress can contribute to the maintenance and promotion of health to all ages and men and women who have suffered from stress and reduced immune function.
또한, 본 발명의 조성물은 약제학적 또는 식품 조성물로 제조될 수 있다.In addition, the compositions of the present invention may be prepared as pharmaceutical or food compositions.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is made into a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen. The pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구 투여 (예컨대, 정맥내 투여, 복강내 투여, 근육내 투여, 피하 투여, 또는 국부 투여)할 수 있다.The pharmaceutical compositions of the present invention may be oral or parenteral (eg, intravenous, intraperitoneal, intramuscular, subcutaneous, or topical).
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 한편, 본 발명의 약제학적 조성물의 투여량은 바람직하게는 1일 당 0.01-100 ㎎/kg(체중)이다.Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. On the other hand, the dosage of the pharmaceutical composition of the present invention is preferably 0.01-100 mg / kg body weight per day.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container. The formulation may be used in any form suitable for pharmaceutical preparations, including powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, external preparations such as ointments, creams, suppositories, and sterile injectable solutions. It may further comprise a dispersant or stabilizer.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 상술한 본 발명의 유효성분뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the composition of the present invention is made of a food composition, it includes not only the active ingredient of the present invention as described above, but also components commonly added in the preparation of food, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and the like. Contains flavors. Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 유효성분 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출 액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다. For example, when the food composition of the present invention is prepared with a drink, in addition to the active ingredient of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract, licorice extract, etc. Can be.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명의 조성물은 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 최소 3종 성분을 포함한다.(Iii) The composition of the present invention contains at least three components of red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria.
(ⅱ) 본 발명의 유효성분은, 스트레스로부터 유발되어 감소된 비장 및 흉선(면역기관)세포의 수, T세포와 B세포(면역세포), IL-2와 IFN-γ(사이토카인), 및 면역글로불린 M, G1, G2a, G2b 및 G3을 유의적으로 증가시켜 면역기능을 증진시키는 효과가 높다. 하여 스트레스로 인한 면역저하로 야기된 질환, 특히 암 및 감기의 예방 및 개선 효과가 있으며, 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균을 각각 복용하였을 때 보다, 본 발명의 복합 유효성분을 포함하는 조성물을 복용하였을 때 상승적(synergic) 효과를 가진다.(Ii) The active ingredient of the present invention includes a reduced number of spleen and thymus (immune organ) cells induced from stress, T cells and B cells (immune cells), IL-2 and IFN-γ (cytokines), and Immunoglobulin M, G1, G2a, G2b and G3 significantly increases the effect of enhancing immune function. It is effective in preventing and improving diseases caused by immunosuppression due to stress, especially cancer and cold, and when the red ginseng extract, shiitake mycelium extract, aloe extract or lactic acid bacteria are respectively taken, the complex active ingredient of the present invention is included. It has a synergic effect when the composition is taken.
(ⅲ) 본 발명의 조성물은 스트레스로 인한 면역기능 저하를 개선하는 효과를 가지고 있어 스트레스로 고통을 받아 면역기능이 저하된 남녀노소 누구에게나 건강유지 및 증진에 기여할 수 있다.(Iii) The composition of the present invention has an effect of improving the immune function lowering due to stress can contribute to the maintenance and promotion of health to all men and women of old age who suffered from stress and the immune function is reduced.
(ⅳ) 또한, 본 발명의 조성물은 천연물질을 유효성분으로 하여 세포독성 및 피부 부작용이 없어 식품 및 약제학적 조성물에 안전하게 적용할 수 있다.(Iii) In addition, the composition of the present invention can be safely applied to food and pharmaceutical compositions, since there is no cytotoxicity and skin side effects using a natural substance as an active ingredient.
이상에서 상세히 설명한 바와 같이, 본 발명은 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 및 유산균으로 구성된 군으로부터 선택되는 최소 3종의 성분을 유효성분으로 포함하는 스트레스로부터 야기되는 면역기능 저하를 개선시키는 면역질환 예방 또는 치료용 조성물을 제공한다. 본 발명의 조성물에서 이용되는 유효성분인 스트레스로부터 유발되어 감소된 비장 및 흉선(면역기관)세포의 수, T세포와 B세포(면역세포), IL-2와 IFN-γ(사이토카인), 및 면역글로불린 M, G1, G2a, G2b 및 G3을 유의적으로 증가시켜 면역기능을 증진시키는 효과가 높다. 하여 스트레스로 인한 면역저하로 야기된 질환, 특히 암 및 감기의 예방 및 개선 효과가 있으며, 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균을 각각 복용하였을 때 보다, 본 발명의 복합 유효성분을 포함하는 조성물을 복용하였을 때 상승적 효과를 가진다. 본 발명의 조성물은 스트레스로 인한 면역기능 저하를 개선하는 효과를 가지고 있어 스트레스로 고통을 받아 면역기능이 저하된 남녀노소 누구에게나 건강유지 및 증진에 기여할 수 있다. 또한, 본 발명의 조성물은 천연물질을 유효성분으로 하여 세포독성 및 피부 부작용이 없어 식품 및 약제학적 조성물에 안전하게 적용할 수 있다.As described in detail above, the present invention provides an immune system for improving immune function deterioration caused by stress including at least three components selected from the group consisting of red ginseng extract, shiitake mushroom mycelium extract, aloe extract and lactic acid bacteria as an active ingredient. Provided is a composition for preventing or treating a disease. Reduced spleen and thymic (immune organ) cells induced by stress, an active ingredient used in the composition of the present invention, T cells and B cells (immune cells), IL-2 and IFN-γ (cytokines), and Immunoglobulin M, G1, G2a, G2b and G3 significantly increases the effect of enhancing immune function. It is effective in preventing and improving diseases caused by immunosuppression due to stress, especially cancer and cold, and when the red ginseng extract, shiitake mycelium extract, aloe extract or lactic acid bacteria are respectively taken, the complex active ingredient of the present invention is included. It has a synergistic effect when the composition is taken. The composition of the present invention has the effect of improving the immune function lowering due to stress can contribute to the maintenance and promotion of health to all men and women of all ages suffering from stress and the immune function is reduced. In addition, the composition of the present invention can be safely applied to food and pharmaceutical compositions because there is no cytotoxicity and skin side effects using a natural substance as an active ingredient.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명 하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples in accordance with the gist of the present invention to those skilled in the art. Will be self explanatory.
실시예Example
실험재료 및 방법Experimental Materials and Methods
시료sample
홍삼추출물, 표고버섯추출물 또는 알로에추출물은 각각의 시료 1 kg에 중량 대비 10 배의 물(10 L)을 첨가하고, 85℃에서 6시간씩 2회 추출 하며, 120 메쉬 체망으로 여과한 다음, 농축 후 분무건조하여 분말화함으로써 실험에 이용하였고, 유산균은 셀바이오텍에서 구입하여 이용하였다.Red ginseng extract, shiitake mushroom extract or aloe extract is added 10 times water (10 L) by weight to 1 kg of each sample, extracted twice at 85 ° C. for 6 hours, filtered through 120 mesh sieve, and concentrated. After spray drying to dry the powder was used in the experiment, lactic acid bacteria were purchased from Cell Biotech.
하기의 표 1과 동일한 조성으로 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균을 포함하는 본 발명의 조성물을 제조하였다:To prepare a composition of the present invention comprising red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria in the same composition as Table 1 below:
상기 표 1의 본 발명 조성물의 조성비는 액상제품 기호에 적합한 성분을 바람직한 제조예로 혼합 조성하였지만, 수요계층, 수요국가 및 사용용도 등 지역적 또는 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio of the composition of the present invention of Table 1 is mixed with the components suitable for the preference of liquid products in a preferred manufacturing example, the composition ratio may be arbitrarily modified according to regional or ethnic preferences such as demand hierarchy, demand country, and usage. .
실험동물Laboratory animals
코아텍 사로부터 C57BL/6 계통의 특정병원체부재(SPF) 자성 6주령 마우스(18-20 g)를 공급받았고, 실험군당 6마리로 할당하였다. 사료는 실험동물용 고형사료((주) 슈퍼피드)를 자유 섭취시켰고, 물은 증류수 제조장치(Milli-Q synthesis A-10, MILLIPORE)에서 제조된 1차 증류수를 멸균하여 자유 섭취시켰다. 동물을 입수할 때에 외관을 육안으로 검사한 후 일주일간 시험을 실시하는 시험동물 사육실에서 순화시키면서 일반증상을 관찰하여 건강한 동물만을 시험에 이용하였다. 본 발명의 투여개시 시 7주령의 마우스의 체중은 20-22 g이었다. 본 시험은 온도 23 ± 3℃, 상대습도 50 ± 10%, 조명시간 12시간(09시 점등 그리고 21시 소등), 환기횟수 10-20 회/시간 및 조도 150-300 Lux로 설정된 순천대학교 제1자연과학대학 16107호 시험동물 사육실에서 실시하였다.Cotech was supplied with C57BL / 6 strain-specific pathogen free (SPF) female 6-week-old mice (18-20 g) and assigned to 6 mice per experimental group. Feed was freely ingested solid feed for experimental animals (Super Feed Co., Ltd.), and water was freely ingested by sterilizing primary distilled water prepared in distilled water manufacturing apparatus (Milli-Q synthesis A-10, MILLIPORE). When the animals were obtained, the external appearance was visually inspected, and then the normal symptoms were observed while being purified in a test animal breeding room where the test was conducted for one week. Only healthy animals were used for the test. The body weight of the mice at 7 weeks of age at the start of the present invention was 20-22 g. This test is composed of Sunchon National University, which is set to temperature 23 ± 3 ℃,
홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균을 각각 멸균수에 녹여 60 kg인 사람이 하루에 2 g 섭취하는 양으로 마우스에 3주간 자유 섭취하도록 하였다. 그 다음에 덱사메타손(5 mg/kg, Sigma-Aldrich)을 복강주사하고 24시간 뒤에 마우스를 경추탈골 시켜 흉선과 비장을 적출하여 흉선과 비장의 세포의 수, T세포와 B세포의 증식, IFN-γ와 면역글로불린 M 분비량을 측정하였다. 한편 본 발명의 조성물 1 및 2는 각 유효성분을 동일한 중량비로 조성물 1은 3 g, 6 g 및 9 g 그리고 조성물 2는 4 g, 8 g 및 12 g으로, 단독 시료 처리와 동일한 방법으로 마우스에 섭취시키고 추가적으로 IL-2의 분비량, 면역글로불린 G1, G2a, G2b 및 G3의 분비량, 비장세포의 T세포와 B세포의 구성비율 및 흉선의 T세포 분화정도를 측정하였다.Red ginseng extract, shiitake mycelium extract, aloe extract or lactic acid bacteria were dissolved in sterile water, respectively, so that 60 kg of humans ingested 2 g per day for free intake for 3 weeks. Then, intraperitoneally inject dexamethasone (5 mg / kg, Sigma-Aldrich), and after 24 hours, distal thoracic bones of the mouse were used to extract the thymus and spleen. γ and immunoglobulin M secretion were measured. Meanwhile, the
또한, 덱사메타손 처리군을 음성 대조군 및 무처리군을 대조군으로 하였다.In addition, the dexamethasone treated group was used as a negative control group and the untreated group as a control group.
비장세포Splenocytes 및 And 흉선세포Thymus cells 수 측정 Can measure
덱사메타손(Sigma-Aldrich) 투여로 감소된 비장과 흉선의 세포 수가 본 발명의 조성물을 처리한 후에 증가하였는지를 관찰하였다. 먼저 마우스의 비장과 흉선을 분리하고, 핀셋 또는 메스를 이용하여 단일 세포 부유액을 만든 다음 RPMI 1640 배양액으로 3회 세척하였다. 이어, 트리판 블루(tryphan blue) 시약(대한과학)을 이용하여 혈구계산반(hemocytometer)으로 생세포수를 측정하였다.It was observed whether the number of spleen and thymus cells decreased by administration of dexamethasone (Sigma-Aldrich) increased after treatment with the composition of the present invention. First, the spleen and thymus of the mouse were separated, a single cell suspension was prepared using tweezers or a scalpel and then washed three times with RPMI 1640 culture. Subsequently, viable cell numbers were measured by a hemocytometer using a tryphan blue reagent (Korea Science).
비장세포Splenocytes 증식 측정 Proliferation measurement
덱사메타손 투여로 감소된 비장세포의 증식 능력이 본 발명의 조성물을 처리한 후에 증가하였는지를 관찰하였다. 비장세포의 부유액을 RPMI 1640 배양액으로 3회 세척하고 5× 106 cells/㎖ 농도가 되도록 희석한 다음 96 웰 플레이트에 웰당 100 ㎕씩 첨가하였다. 이때 비장세포 중 T세포의 증식은 콘카나발린 A(concanavalin A) 및 B세포의 증식은 리포폴리사카리드를 이용하였다. 세포증식 측정은 Cell titer 96? Aqueous One Solution Cell proliferation Assay(Promega, 미합중국)를 이용하였으며, 각각 배양된 배양액 100 ㎕에 셀 티터(Cell titer) 15 ㎕씩 첨가하여 72시간동안 배양한 다음 마이크로플레이트 리더(Microplate Reader,대한과학, falcon)를 이용하여 490㎚에서 흡광도 값을 측정하였다. It was observed whether the proliferative capacity of splenocytes decreased by the administration of dexamethasone increased after treatment of the composition of the present invention. The suspension of splenocytes was washed three times with RPMI 1640 culture and diluted to a concentration of 5 × 10 6 cells / ml, and then 100 μl per well was added to a 96 well plate. At this time, the proliferation of T cells in splenocytes was used for lipopolysaccharide for proliferation of concanavalin A and B cells. Cell proliferation was measured by Cell titer 96 ? Aqueous One Solution Cell Proliferation Assay (Promega, USA) was used and 15 μl of cell titer was added to 100 μl of each culture medium, followed by incubation for 72 hours, followed by microplate reader (Korean Science, falcon). The absorbance value was measured at 490 nm using a).
사이토카인 분비량 측정Cytokine Secretion Measurement
덱사메타손 투여로 감소된 T 세포의 사이토카인 분비량이 본 발명의 조성물을 처리한 후에 증가하였는지를 관찰하였다. T 세포가 분비하는 인터루킨-2(Interleukin-2; IL-2), 인터페론-γ(Interferon-γ: IFN-γ) 농도 측정은 ELISA법을 이용하여 결정하였다. 즉, 평판 마이크로 웰 플레이트에 염소 항-마우스 사이토카인 항체(대한과학)를 코팅 완충액을 이용하여 4℃에서 하룻밤 반응시키고 3% 우 혈청 알부민(BSA)용액으로 2시간 동안 상온에서 블록킹하였다. 앞 실험에서에서 채취한 배양 상층액을 상기 플레이트에 각각 넣고 37℃에서 2시간 동안 반응시킨 다음 바이오틴 항-사이토카인 2차 항체(대한과학)를 첨가하였다. 이어, 아비딘-결합 알카라인 포스페이트(대한과학)를 적당량 첨가하고 37℃에서 2시간 반응시킨 다음 기질로 p-니트로페닐 포스페이트(대한과학)를 첨가하였다. 그 다음, 마이크로플레이트 리더를 이용하여 410 nm와 450 nm에서 흡광도 값을 측정하였다.It was observed whether the cytokine secretion of T cells decreased by the administration of dexamethasone increased after treatment of the composition of the present invention. Interleukin-2 (IL-2) and Interferon-γ (Interferon-γ: IFN-γ) concentrations secreted by T cells were determined by ELISA. That is, the goat anti-mouse cytokine antibody (Korean Science) was plated in a plated microwell plate overnight at 4 ° C using a coating buffer, and blocked with 3% bovine serum albumin (BSA) solution at room temperature for 2 hours. The culture supernatants collected in the previous experiments were put in the plates, respectively, and reacted at 37 ° C. for 2 hours, and then biotin anti-cytokine secondary antibody (Korea Science) was added. Subsequently, an appropriate amount of avidin-bound alkaline phosphate (Korean Science) was added and reacted at 37 ° C. for 2 hours, followed by p-nitrophenyl phosphate (Korean Science) as a substrate. Then, absorbance values were measured at 410 nm and 450 nm using a microplate reader.
면역글로불린 분비량 측정Immunoglobulin Secretion Measurement
덱사메타손 투여로 감소된 B 세포의 면역글로불린 분비량이 본 발명의 조성물을 처리한 후에 증가하였는지를 관찰하였다. B 세포가 분비하는 IgM, IgG1, IgG2a, IgG2b 및 IgG3의 농도 측정은 ELISA법을 이용하여 결정하였다. 구체적 방법은 상기 사이토카인 측정법과 동일하다. It was observed whether the immunoglobulin secretion of B cells reduced by the administration of dexamethasone increased after treatment of the composition of the present invention. The concentration of IgM, IgG1, IgG2a, IgG2b and IgG3 secreted by B cells was determined by ELISA method. The specific method is the same as the cytokine measuring method.
흉선세포의Thymic CD4CD4 와 Wow CD8CD8 수용체 발현량 측정 Receptor expression level measurement
덱사메타손 투여로 감소된 흉선세포의 CD4와 CD8 수용체 발현량이 본 발명의 조성물을 처리 한 후에 증가하였는지를 관찰하였다. 적출한 흉선을 RPMI 1640 배지가 담긴 배양접시에 옮겨 단일세포 부유액을 만들고 PBS 완충액으로 원심 침전(1200rpm, 10분)하여 2회 세척한 후 세포수를 5× 105 개로 조절하였다. 이어, FITC(Fluorescein isothiocyanate)-결합 CD4 항체(항-마우스 CD4)(대한과학) 10 ㎕ 및 PE(phycoerythrin)-결합 CD8 항체(항-마우스 CD8)(대한과학) 10 ㎕의 혼합액을 첨가하여 잘 혼합한 다음 빛을 차단하고 4℃에서 30분 동안 반응하였다. 염색된 세포를 PBS 세척액(1% FBS 및 0.02% 소듐 아지드 포함) 800 ㎕에서 2회 원심 침전하고 침전된 세포들을 세척액 400 ㎕에 다시 부유시켜 유세포 분석기로 분석하였다. FACScan(Coulter XL, 미합중국)을 이용하여 10,000개의 세포에 대하여 전방 빛 산란(FSC) 및 측방산란(90° scatter; SSC) 상에서 세포 절편을 제거하고, 녹색형광(FITC) 및 적색형광(PE)의 2색 면역형광을 각각 x축 및 y축에 도시하여 FACScan 프로그램(Coulter XL,USA)으로 게이팅하고 분석하였다. It was observed whether CD4 and CD8 receptor expression of thymic cells decreased by the administration of dexamethasone increased after treatment with the composition of the present invention. The extracted thymus was transferred to a culture plate containing RPMI 1640 medium to make a single cell suspension, washed twice with centrifugal precipitation (1200 rpm, 10 minutes) in PBS buffer, and the cell number was adjusted to 5 × 10 5 cells. Then, 10 μl of Fluorescein isothiocyanate (FITC) -binding CD4 antibody (anti-mouse CD4) (Korean Science) and 10 μl of PE (phycoerythrin) -binding CD8 antibody (anti-mouse CD8) (Korean Science) were added to the wells. After mixing, the light was blocked and reacted at 4 ° C. for 30 minutes. Stained cells were centrifuged twice in 800 μl PBS wash (containing 1% FBS and 0.02% sodium azide) and the precipitated cells were resuspended in 400 μl wash and analyzed by flow cytometry. FACScan (Coulter XL, United States) was used to remove cell fragments on forward light scattering (FSC) and side scattering (90 ° scattering (SSC)) for 10,000 cells, and to determine the green fluorescence (FITC) and red fluorescence (PE) Two-color immunofluorescence was gated and analyzed with the FACScan program (Coulter XL, USA), plotted on the x and y axes, respectively.
비장세포의Splenocyte CD4CD4 , , CD8CD8 및 And CD19CD19 수용체 발현량 측정 Receptor expression level measurement
비장세포 부유액을 PBS에 5× 105 개로 부유시키고, 세포 부유액에 적당량의 FITC-표지 항체(항-마우스 CD4, CD8 및 CD19)(대한과학)를 가하여 4℃에서 30분간 두었다. 염색이 완료된 세포를 PBS로 1회 세척하고 4% 파라폼 알데히드/PBS로 고정한 다음 FACScan(Coulter, USA)을 이용하여 분석하였다. 별도의 세포 부유액에 FITC 표지 햄스터 IgG(Serotec, 영국)를 가하여 실험한 다음 음성 대조군으로 이용하였으며, 생존세포만을 분석하기 위해 전방 산란/측방 산란 게이팅을 통해 죽은 세포를 배제하였다.Splenocyte suspensions were suspended in PBS at 5 × 10 5 , and appropriate amounts of FITC-labeled antibodies (anti-mouse CD4, CD8 and CD19) (Korea Science) were added to the cell suspensions and left at 4 ° C. for 30 minutes. Stained cells were washed once with PBS, fixed with 4% paraform aldehyde / PBS and analyzed using FACScan (Coulter, USA). FITC-labeled hamster IgG (Serotec, UK) was added to a separate cell suspension and used as a negative control. Dead cells were excluded through forward scattering / side scattering gating to analyze only living cells.
통계학적 방법Statistical method
시험결과는 평균값 ± SD로 나타내었고, 스튜던트 t-test를 이용하여 통계 처리한 후에 p<0.05, p<0.01 수준에서 유의성을 검증하였다.The test results were expressed as the mean value ± SD, and the significance was verified at p <0.05 and p <0.01 levels after statistical treatment using Student's t- test.
실험결과Experiment result
비장세포Splenocytes 및 And 흉선세포Thymus cells 수에 대한 효과 Effect on Number
덱사메타손으로 유발된 마우스의 비장(spleen) 및 흉선(thymus) 세포 수 감소에 대한 홍삼, 표고버섯균사체, 알로에 추출물 또는 유산균의 효과는 다음 표 2 에 기재되어 있다:The effects of red ginseng, shiitake mycelium, aloe extract or lactic acid bacteria on the reduction of spleen and thymus cell numbers in dexamethasone-induced mice are described in Table 2 below:
도 1a-1b 및 상기 표 2에서 볼 수 있듯이, 감소한 비장세포에 대하여 홍삼 추출물만이 세포의 수가 증가하였고, 감소한 흉선세포에 대해서는 유산균을 제외한 다른 시료를 처리한 경우 세포의 수를 증가시켰다. 하지만, 세포의 수를 증가시킨 시료라 할지라도 개별시료의 처리로는 그 효과가 미약함을 알 수 있다.As shown in Figure 1a-1b and Table 2, only the red ginseng extract increased the number of cells for the reduced splenocytes, and increased the number of cells when treated other samples except lactic acid bacteria for the reduced thymic cells. However, even if the sample increases the number of cells, it can be seen that the effect of the treatment of the individual sample is weak.
한편, 덱사메타손으로 유발된 마우스의 비장 및 흉선 세포 수 감소에 대한 본 발명 조성물의 농도별 효과는 다음 표 3과 같다:On the other hand, the concentration-specific effects of the composition of the present invention on the reduction of spleen and thymic cell number of mice induced by dexamethasone are shown in Table 3 below:
도 1c-1d 및 상기 표 3에서 확인할 수 있듯이, 본 발명의 조성물을 처리한 경우 덱사메타손 투여로 감소한 비장세포 및 흉선세포의 수를 유의하게 증가시켰음을 확인할 수 있었다.As can be seen in Figure 1c-1d and Table 3, it was confirmed that the treatment of the composition of the present invention significantly increased the number of splenocytes and thymic cells reduced by dexamethasone administration.
구체적으로, 개별시료 및 본 발명 조성물의 효과를 비교하기 위한 수학식 1은 다음과 같다:Specifically,
상기 수학식 1에 의하면, 상기 표 2에서 최대 효과를 가지는 개별시료인 홍삼 추출물은 대조군에 대해서 비장세포의 수는 4.3%의 증가율을 보이고, 흉선세포의 수는 3.6%의 증가율을 보임에 반해, 조성물 2(8g, 각 유효성분 2 g씩)의 경우 비장세포의 수는 58.9%의 증가율을 보이고, 흉선세포의 수는 24.4%의 증가율을 보임을 알 수 있다. 따라서 본 발명의 조성물이 면역과 관련된 세포의 수를 증가 시키는 데 있어 개별시료 보다 더 우수한 효과를 가지며, 이는 스트레스(덱사메타손의 투여)에 의해 감소된 흉선 및 비장세포의 수를 증가시키는 데 있어 상승적(synergic) 효과를 가짐을 알 수 있다.According to
비장 T세포(Spleen T cells ( CD4CD4 + + 및And CD8CD8 ++ )와 B세포() And B cells ( CD19CD19 ++ )의 비율Of
덱사메타손으로 유발된 마우스의 비장에서 T세포와 B세포의 퍼센트에 대한 조성물의 농도별 효과는 하기 표 4에 기재된 바와 같다:The concentration-dependent effects of the composition on the percentage of T cells and B cells in the spleen of dexamethasone induced mice are shown in Table 4 below:
도 2 및 상기 표 4에서 확인 할 수 있듯이, 본 발명의 조성물 1 및 2 모두 비장세포내의 T세포와 B세포의 비율을 증가시키지는 못하였다. 그러나 덱사메타손 투여로 T세포와 B세포의 비율에는 아무런 변화가 없었다.As can be seen in Figure 2 and Table 4,
흉선 세포의 비율Percentage of thymic cells
덱사메타손으로 유발된 마우스의 흉선에서 흉선세포에 대한 본 발명 조성물의 농도별 효과는 하기 표 5에 정리하였다:The concentration-dependent effects of the compositions on thymic cells in the thymus of dexamethasone-induced mice are summarized in Table 5 below:
도 3 및 상기 표 5에서 볼 수 있듯이, 본 발명의 조성물 1 및 2 모두 덱사메타손 투여로 감소한 흉선세포의 CD4+CD8+ 세포의 수를 유의하게 증가시켰음을 확인할 수 있다.As can be seen in Figure 3 and Table 5, it can be seen that both
비장세포Splenocytes 증식 효과 Proliferative effect
덱사메타손으로 유발된 마우스 비장에서 T세포 및 B세포 성장에 대한 개별시료의 효과는 다음 표 6에 기재되어 있다:The effect of individual samples on T cell and B cell growth in dexamethasone-induced mouse spleens is shown in Table 6 below:
도 4a-4b 및 상기 표 6에서 확인할 수 있듯이, 비장세포 중에서 T세포를 특이적으로 자극하여 증식시키는 항CD3 항체(1 ㎍/㎖)에 대해 표고버섯균사체 추출물 및 알로에 추출물이 대조군에 비해 덱사메타손 투여로 감소한 T세포의 증식을 증가시켰다. 또한, B세포를 특이적으로 자극하여 증식시키는 LPS(10 ㎍/㎖)에 대해 모든 시료들이 대조군에 비해 덱사메타손 투여로 감소한 B세포의 증식을 증가시켰다.As can be seen in Figure 4a-4b and Table 6, the shiitake mushroom mycelium extract and aloe extract for the anti-CD3 antibody (1 ㎍ / ㎖) to specifically stimulate the proliferation of T cells in splenocytes administered dexamethasone compared to the control group Increased T cell proliferation. In addition, for LPS (10 μg / ml) that specifically stimulated and proliferated B cells, all samples increased the proliferation of B cells reduced by dexamethasone administration compared to the control group.
한편, 덱사메타손으로 유발된 마우스 비장에서 T세포 및 B세포 성장에 대한 본 발명 조성물의 효과는 다음 표 7에 기재되어 있다:On the other hand, the effect of the composition of the present invention on T cell and B cell growth in dexamethasone-induced mouse spleen is described in Table 7:
도 4c-4d 및 상기 표 7에서 확인할 수 있듯이, 본 발명 조성물 1 및 2 모두 덱사메타손 투여로 감소한 T세포와 B세포의 증식을 유의하게 증가시켰다.As can be seen in Figure 4c-4d and Table 7, the
사이토카인 분비에 대한 효과Effects on Cytokine Secretion
덱사메타손으로 유발된 마우스 비장에서 T 세포 성장과 IFN-γ 생성 감소에 대한 개별시료의 효과는 다음 표 8에 정리하였다:The effect of individual samples on reducing T cell growth and IFN-γ production in dexamethasone-induced mouse spleens is summarized in Table 8 below:
도 5a 및 상기 표 8에서 확인할 수 있듯이, 항-CD3 항체(1 ㎍/㎖)에 대해 T세포가 증식할 때 분비하는 사이토카인의 한 종류인 IFN-γ는 대조군에 비해 음성 대조군 투여로 감소한 IFN-γ 분비량을 표고버섯균사체 추출물 또는 알로에 추출물이 증가시켰음을 확인할 수 있었다. As can be seen in FIG. 5a and Table 8, IFN-γ, a type of cytokine secreted when T cells proliferate against anti-CD3 antibody (1 μg / ml), was decreased by administration of negative control group compared to control group. It was confirmed that -γ secretion of shiitake mushroom mycelium extract or aloe extract increased.
한편, 덱사메타손으로 유발된 마우스의 비장에서 IL-2와 IFN-γ 생성 감소에 대한 본 발명 조성물의 농도별 효과는 하기 표 9에 기재된 바와 같다:On the other hand, the concentration-specific effects of the composition of the present invention on the reduction of IL-2 and IFN-γ production in the spleen of dexamethasone-induced mice are shown in Table 9 below:
도 5b-5c 및 상기 표 9에서 볼 수 있듯이, 본 발명 조성물 1 및 2 모두 덱사메타손 투여로 감소한 IL-2와 IFN-γ의 분비량을 유의하게 증가시켰다.As can be seen in Figures 5b-5c and Table 9,
구체적으로, 개별시료 및 본 발명 조성물의 효과를 비교하기 위한 수학식 2은 다음과 같다:Specifically,
상기 수학식 2에 의하면, 상기 표 8에서 최대 효과를 가지는 개별시료인 표고버섯균사체 추출물은 대조군에 대해서 IFN-γ의 분비량은 62.7%의 증가율을 보이 나, 조성물 2(16g, 각 유효성분 4 g씩)의 경우 80.2%의 증가율을 보임을 알 수 있다. 따라서 본 발명의 조성물이 IFN-γ의 분비하는데 있어 상승적(synergic) 효과를 가짐을 알 수 있다.According to
면역글로불린 분비에 대한 효과Effects on Immunoglobulin Secretion
덱사메타손으로 유발된 마우스 비장에서 B 세포와 IgM 생성감소에 대한 개별시료의 효과는 다음과 같다:The effect of individual samples on decrement of B cells and IgM in dexamethasone-induced mouse spleens was as follows:
도 6a 및 상기 표 10에서 확인할 수 있듯이, 상기 4 종의 개별시료는 LPS(10 ㎍/㎖)에 대해 B세포가 증식할 때 분비하는 면역글로불린 M은 대조군에 비해 덱사메타손 투여로 감소한 면역글로불린 M 분비량을 증가시켰다.As can be seen in Figure 6a and Table 10, the four individual samples of the immunoglobulin M secreted when the B cells proliferate against LPS (10 ㎍ / ㎖), immunoglobulin M secretion reduced by dexamethasone administration compared to the control group Increased.
도 6b-6f 및 상기 표 11 내지 15에서 확인할 수 있듯이, 본 발명 조성물 1 및 2 모두 덱사메타손 투여로 감소한 면역글로불린 M, G1, G2a, G2b 및 G3의 분비량을 유의하게 증가시켰음을 알 수 있다.As can be seen in Figures 6b-6f and Tables 11 to 15, it can be seen that the
상기 실험결과에서처럼 본 발명의 조성물은 스트레스 호르몬으로 알려진 덱사메타손에 의해 저하된 면역기관과 면역세포의 기능을 유의하게 강화시키는 효과를 가지는 것으로 판단된다. 하여 면역기능이 저하되어 유발되는 질병인 각종 세균성 감염질환과 감기와 같은 바이러스성 질환 환자의 면역기능을 강화시키는 면역기능강화 기능성 소재로 이용될 수 있다.As in the above experimental results, the composition of the present invention is considered to have an effect of significantly strengthening the function of immune organs and immune cells reduced by dexamethasone known as stress hormone. It can be used as an immune enhancing functional material to strengthen the immune function of patients with various bacterial infections and viral diseases such as colds, which are diseases caused by reduced immune function.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
참고문헌references
1. 과학기술정책관리연구소. “연구개발을 위한 한국의 기술 분류 체계”. 1994.1. Institute of Science and Technology Policy Management. “Korea's Technology Classification System for R & D”. 1994.
2. 과학기술처. “생명공학과 산업구조에 관한 조사연구” KIST부설유전공학센터. 1989.2. Ministry of Science and Technology. "Survey on Biotechnology and Industrial Structure" KIST Institute of Genetic Engineering. 1989.
3. “생명공학육성 기본계획-제2단계기획(안)”. 1998.3. “Basic Plan for Biotechnology Development-
4. M.Dibner, Biotechnology Guide U.S.A., Institute for Biotechnology Information(1995).4.M.Dibner, Biotechnology Guide USA , Institute for Biotechnology Information (1995).
5. 박영훈. “생명공학산업의 현황과 전망” 생명공학동향 제4권 3호(1996).5. Park Young-hoon. “The Present Status and Prospect of Biotechnology Industry” Biotechnology Trends Vol. 4, No. 3 (1996).
6. Choi C, Choi IH and Huh K. Effects of Cycloheximide and Dexamethasone on Fas-Mediated Apoptosis in Primary Human Astrocytes. Korean J. Immunol. 1999, 21(4):361-368.6. Choi C, Choi IH and Huh K. Effects of Cycloheximide and Dexamethasone on Fas-Mediated Apoptosis in Primary Human Astrocytes. Korean J. Immunol . 1999, 21 (4): 361-368.
7. Ha TY, Kim HI and Im SY. Effect of Dexamethasone on Different Types of Murine T suppressor Cells. Korean J. Immunol. 1987, 9(1):1-15.7. Ha TY, Kim HI and Im SY. Effect of Dexamethasone on Different Types of Murine T suppressor Cells. Korean J. Immunol . 1987, 9 (1): 1-15.
8. Choi DH, Choi SH, Kim CH, Shin KH, Min BH and Chun BG. Inhibitory Effects of Ginseng Saponin Fractions on Dexamethasone-induced Thymus Apoptosis. Korean J. Ginseng Sci. 1997, 21(3):160-168.8. Choi DH, Choi SH, Kim CH, Shin KH, Min BH and Chun BG. Inhibitory Effects of Ginseng Saponin Fractions on Dexamethasone-induced Thymus Apoptosis. Korean J. Ginseng Sci . 1997, 21 (3): 160-168.
9. Ezekowitz RAB and Hoffman J. Innate immunity . Curr . Opin . Immunol. 1998, 10: 9-53.9.Ezekowitz RAB and Hoffman J. Innate immunity . Curr . Opin . Immunol . 1998, 10: 9-53.
10. Chae SY, Shin SH, Bae MJ, Park MH, Song MK, Hwang SJ and Yee ST. Effect of Arabinoxylane and PSP on Activation of Immune Cells. J Korean Soc Food Sci Nutr. 2004, 33(2):278-286.10. Chae SY, Shin SH, Bae MJ, Park MH, Song MK, Hwang SJ and Yee ST. Effect of Arabinoxylane and PSP on Activation of Immune Cells. J Korean Soc Food Sci Nutr . 2004, 33 (2): 278-286.
11. Shin SH, CHae SY, Ha MH, Jo SK, Kim SH, Byun MW and Yee ST. Effect of Bu-Zhong-Yi-Qi-Tang on B Cell Development. J Korean Soc Food Sci Nutr. 2004, 33(2):271-277.11.Shin SH, CHae SY, Ha MH, Jo SK, Kim SH, Byun MW and Yee ST. Effect of Bu-Zhong-Yi-Qi-Tang on B Cell Development. J Korean Soc Food Sci Nutr . 2004, 33 (2): 271-277.
12. Jain J, Loh C and Rao A. Transciptional regulation of the IL-2 gene. Curr. Opin . Immunol. 1995, 7:333-342.12. Jain J, Loh C and Rao A. Transciptional regulation of the IL-2 gene. Curr. Opin . Immunol . 1995, 7: 333-342.
13. Minami Y, Kono T, Miyazaki T and Taniguchi T. The IL_2 receptor complex: its structure, function and target genes. Annu . Rev . immunol. 1993, 11:245-267.13.Minami Y, Kono T, Miyazaki T and Taniguchi T. The IL_2 receptor complex: its structure, function and target genes. Annu . Rev. immunol . 1993, 11: 245-267.
14. Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, Garcia-Sastre A and Levy DE. Type Ⅰ IFN modulates innate and specific antiviral immunity. J Immunol. 2000, 164:4220-4228.14.Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, Garcia-Sastre A and Levy DE. Type I IFN modulates innate and specific antiviral immunity. J Immunol . 2000, 164: 4220-4228.
15. Hayward AR, Chmura K and Cosyns M. Interferon-gamma is required for innate immunity to cryptosporidium parvum in mice. J. Infect . Dis. 2000, 182:1001-1004.15. Hayward AR, Chmura K and Cosyns M. Interferon-gamma is required for innate immunity to cryptosporidium parvum in mice. J. Infect . Dis . 2000, 182: 1001-1004.
16. Ager A, Callard R, Ezine S, Gerard C and Lopez-Botet M. Immune receptor supplement. Immunol. Today 1996, 17.16. Ager A, Callard R, Ezine S, Gerard C and Lopez-Botet M. Immune receptor supplement. Immunol . Today 1996, 17.
17. Lanier LL and Phillips Jh. Evidence for three types of human cytotoxic lympocyte. Immunol. Today 1986, 7:132.17. Lanier LL and Phillips Jh. Evidence for three types of human cytotoxic lympocyte. Immunol . Today 1986, 7: 132.
18. Petrie HT, Hugo P, Scollay R and Shortman K. Lineage relationships and developmental kinetics of immature thymocytes: CD3, CD4 and CD8 acquisition in vivo and in vitro. J. Exp . Med. 1990, 172:1583-1588.18.Petrie HT, Hugo P, Scollay R and Shortman K. Lineage relationships and developmental kinetics of immature thymocytes: CD3, CD4 and CD8 acquisition in vivo and in vitro. J. Exp . Med . 1990, 172: 1583-1588.
19. Saint-Ruf C, Ungewiss K, Groetrrup M, Bruno L, Fehling HJ and von Boehmer H. Analysis and expression of a cloned pre-T-cell receptor gene. Science 1994, 266:1208.19. Saint-Ruf C, Ungewiss K, Groetrrup M, Bruno L, Fehling HJ and von Boehmer H. Analysis and expression of a cloned pre-T-cell receptor gene. Science 1994, 266: 1208.
20. Shortman K and Wu L. Early T lymphocyte progenitors. Annu . Rev . Immunol. 1996, 14:29-47.20. Shortman K and Wu L. Early T lymphocyte progenitors. Annu . Rev. Immunol . 1996, 14: 29-47.
21 Fearon DT and Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996, 272:50-53.21 Fearon DT and Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996, 272: 50-53.
22. Picker LJ and Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu . Rev . Immunol. 1993, 10:561-591.22. Picker LJ and Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu . Rev. Immunol . 1993, 10: 561-591.
도 1a-1d는 덱사메타손으로 유발된 마우스의 비장(spleen) 및 흉선(thymus) 세포 수 감소에 대한 시료의 효과를 나타낸 그래프이다. 도 1a 및 1b는 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 효과를, 도 1c 및 1d는 본 발명 조성물 1 및 2의 농도별 효과를 나타낸다. 본 발명 조성물 1은 표고버섯균사체 추출물, 알로에 추출물 및 유산균을, 본 발명 조성물 2는 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 및 유산균을 유효성분으로 포함한다. DEX는 덱사메타손 투여군(음성 대조군)을, control은 무처리군(대조군)을 나타낸다.1A-1D are graphs showing the effect of a sample on spleen and thymus cell number reduction in mice induced with dexamethasone. Figures 1a and 1b shows the effect of red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria, Figures 1c and 1d shows the effect of the concentration of the
도 2는 덱사메타손으로 유발된 마우스의 비장에서 T세포와 B세포의 퍼센트에 대한 본 발명 조성물 1 및 2의 농도별 효과를 보여주는 그래프이다.Figure 2 is a graph showing the effect of the concentration of the
도 3은 덱사메타손으로 유발된 마우스의 흉선에서 흉선세포에 대한 본 발명 조성물 1 및 2의 농도별 효과를 보여준다.Figure 3 shows the concentration-specific effects of the
도 4a-4d는 덱사메타손으로 유발된 마우스의 비장에서 T세포 및 B세포 성장에 대한 시료의 효과를 나타낸 그래프이다. 도 4a 및 4b는 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 효과를, 도 4c 및 4d는 본 발명 조성물 1 및 2의 농도별 효과를 나타낸다. 도 4a 및 4c는 항CD3 항체를 0.01, 0.1 및 1 ㎍/㎖로, 도 4b 및 4d는 LPS를 0.1, 1 및 10 ㎍/㎖로 처리하였다.4A-4D are graphs showing the effect of samples on T cell and B cell growth in the spleen of dexamethasone induced mice. 4a and 4b shows the effect of the red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria, Figures 4c and 4d shows the effect of the concentration of the
도 5a-5c는 덱사메타손으로 유발된 마우스의 비장에서 T세포 성장과 사이토카인 생성 감소에 대한 시료의 효과를 나타낸 그래프이다. 도 5a는 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 IFN-γ 분비에 대한 효과를, 도 5b 및 5c는 본 발명 조성물 1 및 2의 IL-2 및 IFN-γ 분비에 대한 농도별 효과를 나타낸다. 도 5a-5c는 항CD3 항체를 0, 0.1 및 1 ㎍/㎖로 처리하였다.5A-5C are graphs showing the effect of samples on reducing T cell growth and cytokine production in the spleen of dexamethasone-induced mice. Figure 5a shows the effect of IFN-γ secretion of red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria, Figures 5b and 5c is a concentration-specific effect on the IL-2 and IFN-γ secretion of the
도 6a-6f는 덱사메타손으로 유발된 마우스의 비장에서 B세포와 면역글로불린 생성 감소에 대한 시료의 효과를 보여준다. 도 6a는 홍삼 추출물, 표고버섯균사체 추출물, 알로에 추출물 또는 유산균의 IgM 분비에 대한 효과를, 도 6b -6f는 본 발명 조성물 1 및 2의 IgM, IgG1, IgG2a, IgG2b 및 IgG3 분비에 대한 농도별 효과를 나타낸다. 도 6a-6f는 LPS를 0, 1 및 10 ㎍/㎖로 처리하였다.6A-6F show the effect of the sample on reducing B cells and immunoglobulin production in the spleen of dexamethasone induced mice. Figure 6a is the effect of the red ginseng extract, shiitake mushroom mycelium extract, aloe extract or lactic acid bacteria on the IgM secretion, Figure 6b-6f is a concentration-specific effect on IgM, IgG1, IgG2a, IgG2b and IgG3 secretion of the
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080033507A KR101102031B1 (en) | 2008-04-11 | 2008-04-11 | Compositions for Preventing or Treating Immune Diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080033507A KR101102031B1 (en) | 2008-04-11 | 2008-04-11 | Compositions for Preventing or Treating Immune Diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090108208A true KR20090108208A (en) | 2009-10-15 |
| KR101102031B1 KR101102031B1 (en) | 2012-01-04 |
Family
ID=41551633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080033507A KR101102031B1 (en) | 2008-04-11 | 2008-04-11 | Compositions for Preventing or Treating Immune Diseases |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101102031B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101339706B1 (en) * | 2013-06-20 | 2013-12-10 | 재단법인 금산국제인삼약초연구소 | A compound for immune strengthen inclusion reducing the bitterness of red ginseng, the extract of immune, and the probiotics |
| US9913823B2 (en) | 2011-10-18 | 2018-03-13 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100590999B1 (en) * | 2004-10-22 | 2006-06-19 | 주식회사 케이티앤지 | Pharmaceutical compositions, comprising red ginseng acid polysacchaide and lentinus edodes, of preventing and treating cancer |
| KR100772007B1 (en) * | 2004-12-21 | 2007-10-31 | 주식회사 유니베라 | An aloe composition for macrophage activation or anticancer |
| JPWO2007013613A1 (en) * | 2005-07-29 | 2009-02-12 | サントリー株式会社 | Composition comprising fucoidan or fucoidan hydrolysis product and immunostimulatory material |
-
2008
- 2008-04-11 KR KR1020080033507A patent/KR101102031B1/en active IP Right Grant
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9913823B2 (en) | 2011-10-18 | 2018-03-13 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
| US9999611B2 (en) | 2011-10-18 | 2018-06-19 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
| US10022351B2 (en) | 2011-10-18 | 2018-07-17 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
| US11096921B2 (en) | 2011-10-18 | 2021-08-24 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
| KR101339706B1 (en) * | 2013-06-20 | 2013-12-10 | 재단법인 금산국제인삼약초연구소 | A compound for immune strengthen inclusion reducing the bitterness of red ginseng, the extract of immune, and the probiotics |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101102031B1 (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100615389B1 (en) | Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease | |
| Chong et al. | Ginseng--is there a use in clinical medicine? | |
| Panossian et al. | Effect of andrographolide and Kan Jang–fixed combination of extract SHA-10 and extract SHE-3–on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture | |
| KR20100105346A (en) | Composition for immune enhancement comprising the extract of young antler, cornus officinalis, ligusticum acutilobum, chinese matrimony vine, yam, aurantii nobilis pericarpium, gastrodia elata blume, agastache rugosa, cinnamomum loureirii, ginseng steamed red and schizandra chinensis, as an active ingredient | |
| Kouttab et al. | Thymomodulin: biological properties and clinical applications | |
| US20070196381A1 (en) | Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions | |
| KR101747139B1 (en) | Composition comprising extracts or fractions of Justicia genus | |
| US20210346455A1 (en) | Pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease | |
| JP2019511521A (en) | Pharmaceutical composition for the prevention or treatment of respiratory diseases comprising kitsunenomago extract | |
| Qian | Modulation of cytokine level and sperm quality of mice by Lycium barbarum polysaccharides | |
| Goth et al. | Effect of cortisone on histamine liberation induced by Tween in the dog. | |
| KR20160021182A (en) | Methods and compositions for enhancing stem cell mobilization | |
| KR101102031B1 (en) | Compositions for Preventing or Treating Immune Diseases | |
| KR101746388B1 (en) | Phamaceutial composition comprising of dichloromethane fraction of Aster yomena for immune enhancing | |
| KR20060092373A (en) | Herb medicinal compositions for prevention and alleviation of childern's atopic eczema or dermatitis | |
| KR100613625B1 (en) | Pharmaceutical composition immunity, and extract of poria | |
| EP1414475B1 (en) | An herbal composition for the treatment and remedy of bronchial respiratory difficulties | |
| Ishihara et al. | Inhibition of decrease in natural killer cell activity in repeatedly restraint-stressed mice by a biological response modifier derived from cultured mycelia of the basidiomycete Tricholoma matsutake | |
| CN109260214A (en) | Application of the paeoniflorin compound in preparation treatment medication for treating pyemia | |
| KR20100011580A (en) | Composition for enhancing immune system function comprising extract of abalone viscera | |
| Tauchi et al. | Enhancement of immunoglobulin A production in Peyer's patches by oral administration of a traditional Chinese medicine, xiao-chai-hu-tang (Shosaiko-to) | |
| KR20150087657A (en) | Composition comprising the purified extract of Eriobotrya japonica Radix for immune activity | |
| JP6595196B2 (en) | Antiallergic agent | |
| KR20190006058A (en) | Composition for Treating Osteoporosis by Chronological Aging | |
| KR20150012711A (en) | Composition comprising lycium chinensis for improving immunity reinforcement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E90F | Notification of reason for final refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20161130 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20171128 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20191114 Year of fee payment: 9 |